Overview
The emphasis of Dr Kreissman's clinical research involves the study of childhood neuroblastoma. Neuroblastoma is the most common extracranial solid tumor of childhood and this disease has a diverse clinical phenotype and prognosis. Dr Kreissman has developed, written, and served as national protocol chairman for 2 clinical trials designed to improve outcome for children with the high risk form of this disease through the Children's Oncology Group (COG). Results of this protocol have been published " A Randomized Study of Purged Versus Unpurged Peripheral Blood Stem Cell Transplant Following Dose Intensive Induction Therapy for High Risk Neuroblastoma" and established the new standard of using unpurged PBSC to support autologous transplant in high risk neuroblastoma. Dr. Kreissman has served as a member of the Neuroblastoma committees for COG. She was involved in designing and implimenting additional new protocols for the treatment of neuroblastoma.
Current Appointments & Affiliations
Professor of Pediatrics
·
2021 - Present
Pediatrics, Hematology-Oncology,
Pediatrics
Member of the Duke Cancer Institute
·
2000 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Response to induction chemotherapy modifies the effect of conventional prognostic factors in high-risk neuroblastoma: A report from the Children's Oncology Group
Journal Article EJC Paediatric Oncology · December 1, 2024 Background: Response to induction chemotherapy has been shown to predict outcome in patients with high-risk neuroblastoma (HR-NB), with those achieving a complete response (CR) having superior outcomes. Methods: We evaluated whether conventional prognostic ... Full text CiteNeuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Journal Article J Natl Compr Canc Netw · August 2024 Neuroblastoma is the most common extracranial solid tumor diagnosed in children. This inaugural version of the NCCN Guidelines for Neuroblastoma provides recommendations for the diagnosis, risk classification, and treatment of neuroblastoma. The informatio ... Full text Link to item CiteImpact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report.
Journal Article Clinical cancer research : an official journal of the American Association for Cancer Research · April 2023 PurposePatients ≥18 months of age with International Neuroblastoma Staging System (INSS) stage 3 unfavorable histology (UH), MYCN-nonamplified (MYCN-NA) tumors have favorable survival rates compared with other high-risk neuroblastoma populations. ... Full text CiteRecent Grants
Addressing Food Insecurity in Transplant and Cellular Therapy Patients with Healthcare-Community Partnerships
ResearchCo Investigator · Awarded by The University of Kansas Medical Center Research Institute, Inc · 2024 - 2029ALTE15N2 STUDY
Clinical TrialPrincipal Investigator · Awarded by Children's Hospital of Philadelphia · 2017 - 2021COG Work Order AAML: 1031--Millennium Pharmaceuticals, Inc.
Clinical TrialPrincipal Investigator · Awarded by Children's Hospital of Philadelphia · 2013 - 2021View All Grants
Education, Training & Certifications
Icahn School of Medicine at Mount Sinai ·
1985
M.D.